PPD Named Best Contract Research Organization

Innovation in drug development recognized at Research Triangle awards

WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced it has been named best contract research organization (CRO) in the Triangle Business Journal’s 2016 Life Sciences Awards.

“Our scientific, medical and operational experts are committed to delivering consistent quality and execution, exceptional customer-aligned service and constant innovation.”

An innovation leader in clinical research, PPD is committed to helping biopharmaceutical clients accelerate the development of life-changing medicines to improve health. PPD is among the largest life-science sector employers in North Carolina’s Research Triangle region, providing services that span clinical development. PPD’s Phase I-IV services are fully integrated with PPD® Laboratories, the industry’s most comprehensive lab services.

“This honor is a testament to the high caliber of PPD professionals and our culture of innovation, focusing on improving delivery of new therapies to patients by reducing the cost and time of drug development for our clients,” said William Sharbaugh, chief operating officer for PPD. “Our scientific, medical and operational experts are committed to delivering consistent quality and execution, exceptional customer-aligned service and constant innovation.”

The honor was presented by the Triangle Business Journal and the event’s title partner BDO May 26 at The Umstead Hotel and Spa in Cary. The awards recognize the accomplishments of innovative individuals and research organizations in the life sciences field in the North Carolina Research Triangle area of Raleigh, Durham and Chapel Hill.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 15,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD and its services contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; consolidation in the pharmaceutical and biotechnology industries; rapid technological advances that make our services or capabilities less competitive; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.

Contacts

PPD Contacts
Media:
Elizabeth Humphrey, +1-910-558-6096
elizabeth.humphrey@ppdi.com
or
Investors:
Nate Speicher, +1-910-558-6783
nate.speicher@ppdi.com

MORE ON THIS TOPIC